CARDIFF ONCOLOGY, INC. Net Change in Cash
CARDIFF ONCOLOGY, INC. (CRDF) reported Net Change in Cash of -$8.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$8.93M.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$27.38M.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$3.00M.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.33M, a 116.40% decline year-over-year.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$34.00M, a 214.04% decline from fiscal 2024.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $29.82M, a 461.70% increase from fiscal 2023.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $5.31M, a 20.53% increase from fiscal 2022.
- CARDIFF ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $4.40M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.27M 10-Q · filed 2026-08-11 | |||||||
| 2026-03-31 | -$8.93M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | -$34.00M 10-K · filed 2026-02-24 | |||||||
| 2025-09-30 | -$41.34M 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | -$40.69M 10-Q · filed 2026-08-11 | |||||||
| 2025-03-31 | -$27.38M 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | $29.82M 10-K · filed 2026-02-24 | |||||||
| 2024-09-30 | -$8.62M 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | $3.85M 10-Q · filed 2025-07-29 | |||||||
| 2024-03-31 | -$3.00M 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $5.31M 10-K · filed 2025-02-27 | |||||||
| 2023-09-30 | -$1.11M 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | $3.02M 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | -$1.33M 10-Q · filed 2024-05-02 | |||||||
| 2022-12-31 | $4.40M 10-K · filed 2024-02-29 | |||||||
| 2022-09-30 | $6.77M 10-Q · filed 2023-11-02 | |||||||
| 2022-06-30 | $9.02M 10-Q · filed 2023-08-09 | |||||||
| 2022-03-31 | $8.11M 10-Q · filed 2023-05-04 | |||||||
| 2021-12-31 | -$119.04M 10-K · filed 2023-03-02 | |||||||
| 2021-09-30 | -$117.82M 10-Q · filed 2022-11-03 | |||||||
| 2021-06-30 | -$120.40M 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | -$116.32M 10-Q · filed 2022-05-05 | |||||||
| 2020-12-31 | $120.79M 10-K · filed 2022-02-24 | $120.79M 10-K · filed 2021-02-25 | ||||||
| 2020-09-30 | $26.21M 10-Q · filed 2021-11-04 | $26.21M 10-Q · filed 2020-11-05 | ||||||
| 2020-06-30 | $17.56M 10-Q · filed 2021-08-05 | $17.56M 10-Q · filed 2020-08-11 | ||||||
| 2020-03-31 | -$918.00K 10-Q · filed 2021-05-06 | -$918.27K 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | -$1.26M 10-K · filed 2021-02-25 | |||||||
| 2019-09-30 | -$2.42M 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | -$661.86K 10-Q · filed 2020-08-11 | |||||||
| 2019-03-31 | -$123.05K 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $3.23M 10-K · filed 2020-02-27 | |||||||
| 2018-09-30 | $6.84M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |